Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does NINTEDANIB ESYLATE Cause Idiopathic pulmonary fibrosis? 11 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Idiopathic pulmonary fibrosis have been filed in association with NINTEDANIB ESYLATE (Ofev). This represents 9.4% of all adverse event reports for NINTEDANIB ESYLATE.

11
Reports of Idiopathic pulmonary fibrosis with NINTEDANIB ESYLATE
9.4%
of all NINTEDANIB ESYLATE reports
5
Deaths
1
Hospitalizations

How Dangerous Is Idiopathic pulmonary fibrosis From NINTEDANIB ESYLATE?

Of the 11 reports, 5 (45.5%) resulted in death, 1 (9.1%) required hospitalization, and 5 (45.5%) were considered life-threatening.

Is Idiopathic pulmonary fibrosis Listed in the Official Label?

Yes, Idiopathic pulmonary fibrosis is listed as a known adverse reaction in the official FDA drug label for NINTEDANIB ESYLATE.

What Other Side Effects Does NINTEDANIB ESYLATE Cause?

Diarrhoea (54) Nausea (24) Decreased appetite (20) Fatigue (20) Vomiting (20) Dyspnoea (18) Weight decreased (17) Off label use (16) Constipation (13) Dizziness (13)

What Other Drugs Cause Idiopathic pulmonary fibrosis?

NINTEDANIB (1,905) PIRFENIDONE (413) TAMSULOSIN (103) TREPROSTINIL (84) SIMVASTATIN (79) METFORMIN (39) MACITENTAN (34) METHOTREXATE (33) ADALIMUMAB (32) AMBRISENTAN (31)

Which NINTEDANIB ESYLATE Alternatives Have Lower Idiopathic pulmonary fibrosis Risk?

NINTEDANIB ESYLATE vs NIRAPARIB NINTEDANIB ESYLATE vs NIRMATRELVIR\RITONAVIR NINTEDANIB ESYLATE vs NIROGACESTAT NINTEDANIB ESYLATE vs NIROGACESTAT HYDROBROMIDE NINTEDANIB ESYLATE vs NIRSEVIMAB

Related Pages

NINTEDANIB ESYLATE Full Profile All Idiopathic pulmonary fibrosis Reports All Drugs Causing Idiopathic pulmonary fibrosis NINTEDANIB ESYLATE Demographics